Advancing Biologic Drug Development with Precision and Efficiency
The GI-SMART™ platform is an innovative technology developed by GI Innovation, designed to create and scale bispecific proteins with high structural stability and biological activity. By integrating advanced computational design with protein engineering, this platform enables the creation of optimized therapeutic molecules for diverse medical applications, including immuno-oncology and allergy treatments.
Core Components and Workflow of the GI-SMART™ Platform
- Identification of Optimal Antibody Fragments:
- Utilizing a sophisticated screening process, the platform identifies effective molecules with robust and specific binding to target antigens.
- Advanced phage display technology scans an extensive scFv (single-chain variable fragment) gene library to select the most effective antibody fragments for therapeutic use.
- GI-SMARTab™ Technology:
- A dedicated sub-technology for the development of bispecific antibodies capable of binding two distinct targets simultaneously, enhancing therapeutic efficacy.
- scFv genes are engineered into antibody production regions, creating high-performance bispecific antibodies with superior antigen-binding capabilities.
- A dedicated sub-technology for the development of bispecific antibodies capable of binding two distinct targets simultaneously, enhancing therapeutic efficacy.
- Structural Optimization Through Variant Evaluation:
- The platform evaluates 24,190 structural variants across critical protein regions to achieve therapeutic excellence:
- 41 hinge variants: Improve flexibility and stability.
- 10 Fc domain variants: Enhance immune system interactions and durability.
- 59 linker variants: Optimize the connection and functionality of bispecific proteins.
- This combinatorial approach accelerates the development of clinically suitable lead candidates.
- The platform evaluates 24,190 structural variants across critical protein regions to achieve therapeutic excellence:
Advantages of the GI-SMART™ Platform
- High Structural Stability: Maintains functional integrity under physiological conditions.
- Efficient Production: Facilitates scalable manufacturing of bispecific proteins, making therapies more accessible.
- Broad Applicability: Adaptable for treating cancers, autoimmune diseases, and allergic conditions.
Therapeutic Innovations
The platform has been instrumental in developing groundbreaking biologic drugs like GI-101 and GI-301, targeting immune-oncology and allergic diseases. Each molecule is precisely optimized for its specific application, offering safe and effective treatment options.
Reflecting GI Innovation’s commitment to patient-centric solutions, the GI-SMART™ platform represents a leap forward in delivering next-generation biologic therapies tailored to unmet medical needs.